SCHEMBL5474686

SCHEMBL5474686

Nc1cccc(-c2cn3ccnc3c(C(N)c3ccncc3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.50
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
GFER P55789 1/20 0.49
SYK P43405 3/20 0.48
CD63 P08962 1/20 0.48
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
NPC1 O15118 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PIK3R1 P27986 1/20 0.39
PIK3CA P42336 1/20 0.39
EPHB4 P54760 8/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4803454 0.77 ALDH1A1 (0.59) AURKAALDH1A1POLBGFERSYK
SCHEMBL5481932 0.76 AURKA (0.50) AURKAALDH1A1POLBGFERSYK
SCHEMBL14431283 0.75 EPHB4 (0.60) AURKAALDH1A1POLBGFERSYK
SCHEMBL5488996 0.74 HTR2C (0.40) LMNA
SCHEMBL5474690 0.74 EPHB4 (0.64) SYKEPHB4
SCHEMBL2216977 0.71 AURKA (0.77) AURKAALDH1A1POLBGFERSYK
SCHEMBL5477740 0.70 AURKA (0.52) AURKAALDH1A1POLBGFERSYK
SCHEMBL24864099 0.70 AURKA (0.61) AURKAALDH1A1POLBGFERSYK
SCHEMBL12514839 0.69 AURKA (0.79) AURKASYKCD63EPHB4
SCHEMBL29664463 0.67 AURKA (0.64) AURKAALDH1A1POLBGFERSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259164-B2 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity CGI PHARMACEUTICALS, INC. (US) 2007-08-21 US disclosed
WO-2005019220-A9 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC (US) 2005-06-02 WO disclosed
US-20050085484-A1 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity GILEAD CONNECTICUT, INC. 2005-04-21 US disclosed
WO-2005019220-A2 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY CELLULAR GENOMICS INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085484-A1 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity ERBB4, MAP4K4, EPHB4 AURKA 202/4885ALDH1A1 912/4885POLB 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.